Table II.
Allocation of healthy men to infusion treatment groups.
| Treatment group | Dose | Subject number |
||||
|---|---|---|---|---|---|---|
| Vehicle | — | 2 | 3 | 9 | 10 | 8 |
| KP10, KP54 or GnRH | 0.1 nmol/kg/h | 1 | 4 | 5 | 6 | 7 |
| KP10, KP54 or GnRH | 0.3 nmol/kg/h | 1 | 4 | 7 | 8 | 10 |
| KP10, KP54 or GnRH | 1.0 nmol/kg/h | 2 | 3 | 5 | 6 | 9 |
Ten different 3 h intravenous infusions were administered in healthy men: vehicle; 0.1, 0.3 or 1.0 nmol/kg/h kisspeptin-10 (KP10); 0.1, 0.3 or 1.0 nmol/kg/h kisspeptin-54 (KP54); 0.1, 0.3 or 1.0 nmol/kg/h GnRH. In order to directly compare the effects of equimolar doses of kisspeptin-10, kisspeptin-54 and GnRH, the same combination of subjects (numbered 1–10) received the same dose of each peptide. Study visits for individual patients were scheduled a minimum of a week apart and performed in the random order.